These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3554083)

  • 1. Activity of epirubicin in combination chemotherapy of advanced ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.
    Eckhardt S; Szántó J; Cerar O; Chylak V; Hernádi Z; Hindy I; József S; Juhos E; Kolaric K; Kopecny J
    Oncology; 1987; 44(2):69-72. PubMed ID: 3554083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European Oncology Group Study.
    Eckhardt S; Juhos E; Hindy I; Jelic S; Koza I; László G; Mechl Z; Nagykálnay T; Pawlicki M; Schoket Z
    Oncology; 1988; 45(6):409-12. PubMed ID: 3054671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
    Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
    Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of 3-drug therapy in patients with advanced ovarian cancer].
    Kwaśniewska-Rokicińska C; Kaleta B; Kumor-Głodny T
    Ginekol Pol; 1989 Feb; 60(2):86-9. PubMed ID: 2680790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epirubicin in combination chemotherapy of metastasized breast cancer (VEC) and advanced ovarian cancer (PEC)].
    Christmann D
    Onkologie; 1986 Aug; 9 Suppl 1():11-2. PubMed ID: 3528966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
    Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
    Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients.
    Williams CJ; Stevenson KE; Buchanan RB; Whitehouse JM
    Cancer Treat Rep; 1979; 63(11-12):1745-53. PubMed ID: 393378
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.
    Eckhardt S; Hernádi Z; Thurzó L; Telekes A; Sopkova B; Mechl Z; Pawlicki M; Kerpel-Fronius S
    Oncology; 1990; 47(4):289-95. PubMed ID: 2195412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide.
    Bezwoda WR
    Med Pediatr Oncol; 1986; 14(1):26-9. PubMed ID: 3512971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery.
    Pickel H; Petru E; Lahousen M; Stettner H; Lehnert M
    Oncology; 1989; 46(4):222-5. PubMed ID: 2662087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
    Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
    J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
    Kobayashi H; Hayata T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
    Krommer CF; Szalai JP
    Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.